Latest news

- The confirmatory clinical, safety and efficacy study for AVT04, biosimilar candidate to Stelara® (ustekinumab) met its primary endpoint. - AVT04 (ustekinumab) is part of a broader pipeline of Alvotech’s biosimilars and...

-          Results from pharmacokinetic (PK) similarity study demonstrate bioequivalence of AVT04 (ustekinumab) to the reference product Stelara® Reykjavik, ICELAND (May 16, 2022) – Alvotech Holdings S.A. (“Alvotech”), a global biotech...

Reykjavik and Los Angeles (May 11, 2022) – Alvotech Holdings S.A. (“Alvotech S.A.”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and...

Alvotech and Oaktree Acquisition Corp. II establish financing facilities to enhance the company’s capital position and to replace any redeemed capital as part of their proposed merger. Parties agree to...

Upon launch, HUKYNDRA® will be one of two citrate-free, high-concentration adalimumab biosimilars on the European market. All intellectual-property disputes related to market entry of Alvotech’s AVT02 (adalimumab) in the U.S....

Alvotech expects AVT02 (adalimumab) will be marketed in the U.S., subject to regulatory approval, on July 1, 2023. All ongoing U.S. disputes between AbbVie and Alvotech have been resolved, including...

Alvotech is the only known company to have both developed a high-concentration biosimilar to Humira and conducted a switching study to support interchangeability. Reykjavik, Iceland (February 28, 2022) — Alvotech...

Fuji and Alvotech partnership now covers six proposed biosimilar products. Reykjavik, Iceland & TOKYO, JAPAN (February 23, 2022) — Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on...

Reykjavik, Iceland & Leiden, The NetherlandS (February 2, 2022) — Alvotech Holdings S.A. (“Alvotech”), a global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients...

Reykjavik (January 18, 2022) — Alvotech Holdings S.A. (“Alvotech”), a leading global biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients worldwide, and Oaktree Acquisition...

Health Canada rules that 40 mg/0.4 mL and 80 mg/0.8 mL presentations of SIMLANDI™ are not subject to the statutory stay, clearing the way for the launch in the Canadian...

Alvotech received approval for AVT02 (100 mg/mL), the company’s high concentration biosimilar to Humira® (adalimumab), from the European Commission (EC) on Nov. 15. The centralized marketing authorization in the European...

-      Alvotech is a leading pure play biosimilar platform focused on the development and manufacture of high-quality biosimilar medicines for global markets. Biosimilars are therapeutic equivalents to biologics, a rapidly...

U.S. Federal Judge Grants Alvotech’s Motion to Dismiss AbbVie’s lawsuit alleging misappropriation of trade secrets

Reykjavik, Iceland (September 20, 2021) – Alvotech, a multinational biopharmaceutical company focused on the development and manufacturing of high quality biosimilars for global markets, today announced that the FDA is...

Alvotech, today welcomed the positive opinion of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending the approval of Alvotech‘s high-concentration AVT02 (100 mg/mL), a...

A good collaboration between the University, scientific community and business world is crucial for development and innovation. The partnership of Alvotech and the University of Iceland, has contributed to the...

Alvotech, today announced top-line results from a randomized study in patients that demonstrate bioequivalence of repeated switches between administration of Humira® (adalimumab) and Alvotech’s high-concentration biosimilar candidate, AVT02 (100 mg/mL)...

Approximately 530 participants will be enrolled in a comparative, confirmatory efficacy and safety study for AVT04 in plaque psoriasis, across Central and Eastern European countries.  AVT04 Pharmacokinetic (PK) comparability...